The Global Hitone deacetylase HDAC inhibitors market is estimated to grow at CAGR of 7% during the forecast period. Histone Deacetylase (HDAC) inhibitors are a relatively new family of anti-cancer drugs that cause death, apoptosis, and cell cycle arrest in cancer cells, by regulating epigenetic or non-epigenetic regulation. Vorinostat, romidepsin, belinostat, and panobinostat, four HDAC inhibitors used to treat cutaneous and peripheral T-cell lymphoma and multiple myeloma, were approved by the FDA in March 2018, after clinical trials in cancer patients. Many additional HDAC inhibitors are being developed for the treatment of haematological and solid cancers at various levels of clinical development. Histone deacetylase inhibitors are new chemicals with the potential property in progenosis treatment and cancer diagnosis. Inhibitors of histone deacetylase accumulate acetylated nuclear histone in both normal tissues and tumours. As a result of the inhibition, transcription factors such as estrogen receptor-alpha, p53, and GATA-1 are acetylated, and these enzymes are found in Plants, mammals, bacteria, and fungus.The global rise in cancer prevalence, which has resulted in a greater demand for better and more effective therapies, is driving the global histone deacetylase inhibitors market. Cancer is the world's second leading cause of mortality, according to the World Health Organization. In 2018, cancer was responsible for an estimated 9.6 million deaths globally. Cancer accounts for around one-sixth of all deaths globally, with poor and middle-income countries accounting for over 70% of all deaths. Furthermore, increased collaboration among histone deacetylase inhibitor producers, as well as research and development on cancer and other chronic diseases, are likely to drive the growth of the market.

In December 2015- Chipscreen Biosciences announced that the Chinese Food and Drug Administration approved Chidamide (Epidaza®), the world's first orally administered and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patient. Chidamide is an orally bioavailable, low-nanomolar inhibitor of cancer-associated histone deacetylase (HDAC) enzymes with superior pharmacology and tolerability characteristics, when compared to other HDAC inhibitors such as benzamides and non-benzamides.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Competitive Landscape- Celgene Corporation., Celleron Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG., Acetylon Pharmaceuticals, Inc.,  AstraZeneca plc., Merck & Co., Inc. and Pfizer Inc., among others.   

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Hitone Deacetylase HDAC Inhibitors Market Segmentation

By Type

    • Oncology

    • Neurology

    • Others

By Application

    • Hospital

    • Oncology Clinic

    • Others

Global Hitone deacetylase HDAC inhibitors market is segmented by Region 

North America

    • United States 

    • Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• Japan

• India

• Rest of Asia-Pacific 

Rest of World

    • Latin America

    • The Middle East And Africa